Patents Issued in August 9, 2018
-
Publication number: 20180221273Abstract: Methods and compositions for the treatment of pain associated with inflammation in a patient by transdermal delivery of antioxidant to increase glucose uptake and anti-inflammatory cytokines that act to reduce pain.Type: ApplicationFiled: March 19, 2018Publication date: August 9, 2018Inventor: KENNETH RUSSELL
-
Publication number: 20180221274Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.Type: ApplicationFiled: October 13, 2017Publication date: August 9, 2018Inventor: Alan Meyer
-
Publication number: 20180221275Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: December 21, 2017Publication date: August 9, 2018Inventors: Feng Gao, Frank Scott Atchley, Gregory James Griscik, Christopher Joseph DiNovi, Phillip M. Hulan, Diane L. Gee, Gerd Kobal
-
Publication number: 20180221276Abstract: A wellness drink is disclosed comprising a mixture of apple cider vinegar, aloe vera, lemon juice, honey, olive oil and at least two spices selected from cayenne pepper, cinnamon, turmeric and ginger. The wellness drink may be high pressure processed to cold pasteurize the drink and then refrigerated and bottled. The typical ten ounce serving for an adult may be taken in the morning with breakfast. The drink may be sold comprising the liquid and spice ingredients without the water to save weight and then mixed with pure water. If taken on a regular basis, the wellness drink may reduce abdominal pain, belching and bloating and induce weight loss and a general sense of well-being. The drink tastes like apple cider with added spices and has a dark yellow orange color. Other forms include capsule, a tea bag, a spice pack and a pill.Type: ApplicationFiled: February 7, 2017Publication date: August 9, 2018Applicant: Drink NOVE, LLCInventors: Chris V. Malham, Natalie Dawn Malham
-
Publication number: 20180221277Abstract: The invention generally relates to the field of drug delivery. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for the transdermal delivery of drugs.Type: ApplicationFiled: November 8, 2017Publication date: August 9, 2018Inventors: Seungpyo Hong, Yang Yang
-
Publication number: 20180221278Abstract: The present invention provides a sustained release formulation of an active pharmaceutical ingredient (“API”). In particular, the sustained release formulation is adapted for topical administration or administration via injection and comprises a nanoemulsion of oil-in-water. In some embodiments, the API is an ophthalmic API. The present invention also provides a method for treating an eye disorder using a sustained release formulation. In one particular embodiment, the invention provides methods for treating dry eye syndrome using a sustained release formulation comprising a nanoemulsion of oil-in-water and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Applicant: Ocugen, Inc.Inventors: Rasappa Arumugham, Arun K. Upadhyay
-
Publication number: 20180221279Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.Type: ApplicationFiled: April 9, 2018Publication date: August 9, 2018Inventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
-
Publication number: 20180221280Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.Type: ApplicationFiled: January 31, 2018Publication date: August 9, 2018Inventors: Karine Fabio, Joseph J. Guarneri, Kieran Curley, Marshall L. Grant, Andrea Leone-Bay
-
Publication number: 20180221281Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template.Type: ApplicationFiled: January 16, 2018Publication date: August 9, 2018Applicant: AKINA, INC.Inventors: Kinam Park, Ghanashyam S. Acharya, Haesun Park
-
Publication number: 20180221282Abstract: A process for drying a spray dried dispersion, comprising: a) providing a spray-dried dispersion comprising particles wherein the particles comprise an active agent and a polymer and optionally one or more surfactants, the dispersion having an average particle diameter of less than about 100 m; b) blending an amount of silicon dioxide with the dispersion to form a dispersion-silicon dioxide blend, wherein the amount of silicon dioxide relative to the amount of dispersion is between about 0.5 and 2.0% by weight; c) drying the blend with a secondary dryer.Type: ApplicationFiled: July 29, 2016Publication date: August 9, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Yung-Chi Lee, David Harris, Justin David Moser, Michael McNevin, Amber Broadbent, Robert Hall, Ari Ericson
-
Publication number: 20180221283Abstract: The present application relates to a method for the preparation of a nanosuspension comprising nanoparticles of at least one natural material and an extract of at least one natural material, wherein the method comprises the steps of providing particles of at least one natural material having a particle size (D100) of less than 320 ?m; providing an extract of at least one natural material; dispersing said particles of at least one natural material and said extract of at least one natural material in a solvent; and milling the dispersion to a particle size (D90) of below 1000 nm (D90<1000 nm). Furthermore, the present application also relates to a nanosuspension prepared according to said method, and the use of such nanosuspension for the preparation of a medicament and/or nutritional supplement.Type: ApplicationFiled: August 4, 2016Publication date: August 9, 2018Applicant: Apurano Life sciences GmbHInventor: Werner BRAND
-
Publication number: 20180221284Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Inventors: Henrik NILSSON, Roland RUPP
-
Publication number: 20180221285Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.Type: ApplicationFiled: March 23, 2018Publication date: August 9, 2018Inventors: Indrajit Ghosh, Jia-Ai Zhang
-
Publication number: 20180221286Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.Type: ApplicationFiled: January 18, 2018Publication date: August 9, 2018Inventors: Mohan Kabadi, Jerome J. Schentag
-
Publication number: 20180221287Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: April 9, 2018Publication date: August 9, 2018Applicant: Rani Therapeutics, LLCInventor: Mir Imran
-
Publication number: 20180221288Abstract: A capsule excellent in enteric property with the assumption that gelatin is used as a main base material of the capsule coating. An alkali-treated gelatin and carrageenan are contained as base materials of the capsule coating. In the gastric (aqueous) environment, the alkali-treated gelatin which is positively (+) charged coexists with the carrageenan which is negatively (?) charged, and amino groups (NH4+) in the gelatin react with sulfate groups (SO3?) in the carrageenan so that the capsule coating is insolubilized. On the other hand, in the intestinal (aqueous) environment, the alkali-treated gelatin which is negatively (?) charged coexists with the carrageenan which is negatively (?) charged, and the amino groups (NH4+) in the gelatin are repulsive to the sulfate groups (SO3?) in the carrageenan so that the capsule coating quickly disintegrates and dissolves.Type: ApplicationFiled: August 10, 2016Publication date: August 9, 2018Applicant: SUNSHO PHARMACEUTICAL CO. LTDInventors: Takayuki FUKASAWA, Kenichi KOYAMA, Tomoya SUZUKI
-
Publication number: 20180221289Abstract: In one aspect, the invention provides therapeutic agent nanoparticles coated with cholesteryl esters, formulations of the nanoparticles suitable for injection, methods for administering therapeutic agents and for treating diseases and conditions treatable by the therapeutic agents using the formulations. In a related aspect, the invention provides synthetic high density lipoprotein nanoparticles useful for therapeutic agent delivery, and methods for their preparation and use.Type: ApplicationFiled: August 8, 2016Publication date: August 9, 2018Applicant: Autotelic LLCInventor: Vuong Trieu
-
Publication number: 20180221290Abstract: The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Romi Barat SINGH, Ashish KUMAR, Rajesh Srikrishan SHEAR, Satish Kumar JAIN, Paras P. JAIN
-
Publication number: 20180221291Abstract: The present invention provides a process for forming Janus particles. The novel application of the Janus particles is also disclosed in the present invention. In particular, the Janus particles have an average diameter less than 10 nm and a peak between 2850 and 2921 cm?1 in Fourier transform infrared spectrum.Type: ApplicationFiled: April 9, 2018Publication date: August 9, 2018Inventors: Huan-Tsung Chang, Tzu-Heng Chen, Arun Prakash Periasamy
-
Publication number: 20180221292Abstract: The present invention provides Janus particles and a novel vesicle. In particular, the novel vesicle comprises a plurality of the Janus particles. The Janus particles have symmetric and asymmetric stretching vibrations of CH2 at about 2920 and 2850 cm?1, each with a shoulder, in Fourier transform infrared spectrum.Type: ApplicationFiled: April 9, 2018Publication date: August 9, 2018Inventors: Huan-Tsung Chang, Tzu-Heng Chen, Arun Prakash Periasamy
-
Publication number: 20180221293Abstract: Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.Type: ApplicationFiled: October 31, 2016Publication date: August 9, 2018Inventors: Justin Hanes, Katharina Maisel, Laura Ensign, Richard Cone
-
Publication number: 20180221294Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Inventors: Jan-Otto CARLSSON, Anders JOHANSSON, Marten ROOTH
-
Publication number: 20180221295Abstract: The present invention relates to electrospun fibres containing: i) a first and a second hydrophilic fibre-forming polymer that is soluble in a hydrophilic solvent, ii) a bioadhesive substance that is slightly soluble in said hydrophilic solvent, iv) a drug substance, wherein the first hydrophilic polymer has a solubility in water at 37° C. that is at least 10 times greater than the solubility in water at 37° C. of the second hydrophilic fibre-forming polymer, and wherein the bioadhesive substance is present in solid form.Type: ApplicationFiled: January 29, 2018Publication date: August 9, 2018Applicant: DERMTREAT APSInventors: Jens Hansen, Martin Eduardo Santocildes Romero
-
Publication number: 20180221296Abstract: A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication.Type: ApplicationFiled: February 8, 2018Publication date: August 9, 2018Inventors: Terrence Fletcher Holekamp, Lawrence Gerard Lenke, Michael Patrick Kelly
-
Publication number: 20180221297Abstract: Transdermal drug delivery devices and systems with improved adhesion are disclosed. The transdermal drug delivery devices, or patches, include an integrated overlay that provides a drug-free adhesive perimeter designed to avoid affecting delivery of drug from the device. Also disclosed are methods of manufacturing the transdermal drug delivery devices that include incorporating an integrated overlay onto a TDS patch.Type: ApplicationFiled: February 2, 2018Publication date: August 9, 2018Inventor: Kirti H. Valia
-
Publication number: 20180221298Abstract: The present invention provides a transdermal patch comprising: a drug-containing layer comprising (R)-dihydroetorphine, or a salt or a hydrate thereof, and a poly(meth)acrylate; and a backing layer.Type: ApplicationFiled: July 28, 2016Publication date: August 9, 2018Applicant: Euro-Celtique S.A.Inventors: Steve WHITELOCK, Deborah Phyllis HARDING, Helen JOHNSON, Kevin SMITH, Gill MUNDIN
-
Publication number: 20180221299Abstract: The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by the mean in vivo plasma concentration of (R)-dihydroetorphine achieving at least 50% of its Cmax in less than 20 hours, preferably in less than 18 hours and more preferably in less than 12 hours, after application of the system to the skin of a human subject, e.g. when based on the mean plasma concentration versus time curve.Type: ApplicationFiled: July 28, 2016Publication date: August 9, 2018Applicant: EURO-CELTIQUE S.A.Inventors: Steve WHITELOCK, Deborah Phyllis HARDING, Helen JOHNSON, Kevin SMITH, Gill MUNDIN
-
Publication number: 20180221300Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and and C) optionally an additional skin contact layer.Type: ApplicationFiled: May 20, 2015Publication date: August 9, 2018Applicants: LTS LOHMANN Therapie-Systeme AG, UCB Pharma GmbHInventors: Marco Emgenbroich, Johannes Josef Leonhard, Kristina Kassner, Aurélia Lappert
-
Publication number: 20180221301Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Inventors: Kristin Jackson, Kenneth J. Miller
-
Publication number: 20180221302Abstract: The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).Type: ApplicationFiled: August 15, 2016Publication date: August 9, 2018Inventors: Evan C. Unger, Edmund Marinelli
-
Publication number: 20180221303Abstract: Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.Type: ApplicationFiled: July 19, 2016Publication date: August 9, 2018Inventor: Guido Grentzmann
-
Publication number: 20180221304Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.Type: ApplicationFiled: January 31, 2018Publication date: August 9, 2018Inventors: Andrea Small-Howard, Helen Turner
-
Publication number: 20180221305Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.Type: ApplicationFiled: March 30, 2018Publication date: August 9, 2018Inventor: Lanny Leo Johnson
-
Publication number: 20180221306Abstract: Disclosed herein are pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.Type: ApplicationFiled: March 15, 2018Publication date: August 9, 2018Inventors: Per Borgström, Adrian Chrastina, Veronique Baron
-
Publication number: 20180221307Abstract: The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S1) and a second segment (S2); wherein the first segment (S1) contains at least a first pharmacologically active ingredient (A1) and/or the second segment (S2) contains at least a second pharmacologically active ingredient (A2); and the segment (S1) and/or the segment (S2) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.Type: ApplicationFiled: January 30, 2018Publication date: August 9, 2018Applicant: GRÜNENTHAL GMBHInventors: ANJA GEIßLER-FICHTNER, Klaus Wening, Lutz Barnscheid, Jana Pätz
-
Publication number: 20180221308Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Johannes BARTHOLOMAEUS, Iris ZIEGLER
-
Publication number: 20180221309Abstract: Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a ?-glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the ?-glucan to increase immunogenicity of the fungus.Type: ApplicationFiled: February 1, 2018Publication date: August 9, 2018Inventors: Aaron Kurt Neumann, Harry Craig Pappas, Matthew Graus
-
Publication number: 20180221310Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 26, 2016Publication date: August 9, 2018Inventors: Philippe GUEDAT, Pierre MINIOU
-
Publication number: 20180221311Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.Type: ApplicationFiled: March 31, 2018Publication date: August 9, 2018Inventors: Carolyn L. TWOMEY, Gareth CLARKE, Samuel ZAIDSPINER
-
Publication number: 20180221312Abstract: N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (compound 4), a known chemokine modulator, in combination with colchicine is useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity, interleukin-1 (IL-1) activity, and/or myeloperoxidase (MPO) activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of such diseases/conditions.Type: ApplicationFiled: September 12, 2017Publication date: August 9, 2018Inventors: Payal NANAVATI, Johan HOEGSTEDT, Jesse HALL
-
Publication number: 20180221313Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.Type: ApplicationFiled: August 8, 2016Publication date: August 9, 2018Applicant: Centre National De La Recherche Scientifique (CNRS)Inventors: Yves COLIN, Jean-Francois GIRMENS, Olivier HERMINE, Emmanuel HERON, Michel PAQUES
-
Publication number: 20180221314Abstract: The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Romi Barat SINGH, Kalaiselvan RAMARAJU, Balaram MONDAL, Ashish KUMAR, Suchitra KAUSHIK
-
Publication number: 20180221315Abstract: Described herein is a method for treating a medical condition in a patient, the method comprising: administering to a patient in need (thereof a pharmaceutical composition comprising a therapeutically effective amount of (i) a first therapeutic agent which is acamprosate or a pharmaceutically acceptable salt thereof and (ii) a second therapeutic agent which is D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, an alkylated D-cycloserine, or a precursor of D-cycloserine.Type: ApplicationFiled: August 4, 2016Publication date: August 9, 2018Inventors: Steven L. JOHNS, Craig A. ERICKSON
-
Publication number: 20180221316Abstract: This document provides methods and materials for reducing the degree of damage to tissue transplanted into a mammal following transplantation. For example, methods and materials for using abscisic acid to reduce tissue damage to vascularized tissue transplanted into a mammal following reperfusion of that vascularized tissue are provided.Type: ApplicationFiled: August 3, 2016Publication date: August 9, 2018Inventor: Agnes NAGY
-
Publication number: 20180221317Abstract: The invention relates to a composition for the treatment of superficial lesions, in particular skin lesions, mucous membrane lesions and/or nail lesions, an applicator comprising such a composition and the use of such a composition. The composition comprises an effective amount of trichloroacetic acid, at least one thickener, and at a physiologically acceptable solvent. And is effective against a plethora of superficial lesions selected from the group consisting of viral warts, verrucae, water warts (molluscum contagiosum), corns and calluses, and skin hyperpigmentation: age spots, solar lentigo, senial lentigo, acne, keratosis pilaris, actinic keratosis, mouth ulcers (canker sores), cold sores, ingrown toenails, onychomycosis, eyelid xanthelasma.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Applicant: Progressare Medinvest B.V.Inventors: Maikel HENDRIKS, Pieternella BOUTER, Katarzyna KOLODZIEJ
-
Publication number: 20180221318Abstract: The present invention provides compositions, methods and kits for treating acne and other skin conditions influenced by P. acnes, which combine administration of low levels of at least one C2 to C5 polycarboxylic acid and blue light to skin in need of treatment for such conditions.Type: ApplicationFiled: February 8, 2017Publication date: August 9, 2018Inventors: Julie Marie Bianchini, Kimberly A. Capone, Kelly A. Dunn, Ali Fassih, Davide Miksa, Barry Setiawan, Michael D. Southall, Liliam A. Moreira
-
Publication number: 20180221319Abstract: Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.Type: ApplicationFiled: February 8, 2018Publication date: August 9, 2018Inventor: Matthew DURING
-
Publication number: 20180221320Abstract: Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.Type: ApplicationFiled: August 16, 2016Publication date: August 9, 2018Inventors: Christopher F. Rose, Franck Rousseau
-
Publication number: 20180221321Abstract: The invention relates to methods and related compositions for enhancing cancer therapy and in particular glutaminase inhibitor therapy. The methods involve methods for identifying patients susceptible to glutaminase inhibitor therapy as well as sensitizing patients to glutaminase inhibitor therapy.Type: ApplicationFiled: February 6, 2018Publication date: August 9, 2018Applicant: Massachusetts Institute of TechnologyInventors: Alexander Muir, Matthew Vander Heiden, Laura Danai, Dan Yi Gui
-
Publication number: 20180221322Abstract: Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.Type: ApplicationFiled: November 22, 2017Publication date: August 9, 2018Inventors: Bo Martinsen, Leif Andreas Riege